Zogenix, Inc. reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome. The study results, which are consistent with those reported in Study 1, Zogenix’s first pivotal Phase 3 study, successfully met the primary endpoint and all key secondary endpoints, demonstrating that ZX008, at a dose of 0.5 mg/kg/day (maximum 20 mg/day), is superior to placebo when added to a stiripentol regimen.
July 19, 2019
Poststroke Seizures May Mimic Stroke Recurrence and Should Be Examined Carefully for Appropriate Treatment
Poststroke seizures may worsen or cause the reappearance of neurological deficits and consciousness impairment; they can be also misinterpreted as stroke recurrence and lead to delayed treatment with antiepileptic drugs.
July 18, 2019
Systematic Review Highlights the Value of the Epilepsy Specialist Nurse to Patients, Families and Other Health Care Professionals
The ESPENTE study creates much needed context to the argument for the development of the Epilepsy Specialist Nurses as an integral part of the care provided to people with epilepsy, their family and carers.